Seeing Is Believing
Currently out of the existing stock ratings of Jason Gerberry, 176 are a BUY (65.43%), 63 are a HOLD (23.42%), 30 are a SELL (11.15%).
Analyst Jason Gerberry, currently employed at BAML, carries an average stock price target met ratio of 64.31% that have a potential upside of 30.47% achieved within 287 days.
Jason Gerberry’s has documented 561 price targets and ratings displayed on 53 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on PROK, ProKidney Corp. at 30-Jun-2025.
Analyst best performing recommendations are on PROK (PROKIDNEY CORP.).
The best stock recommendation documented was for PROK (PROKIDNEY CORP.) at 6/30/2025. The price target of $1 was fulfilled within 8 days with a profit of $0.41 (69.49%) receiving and performance score of 86.86.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$205
$12.55 (6.52%)
$215
2 months 5 days ago
(13-May-2025)
12/14 (85.71%)
$27.59 (15.55%)
285
Buy
$216
$23.55 (12.24%)
$214
2 months 20 days ago
(28-Apr-2025)
23/26 (88.46%)
$22.49 (11.62%)
431
Buy
$250
$57.55 (29.90%)
$241
2 months 21 days ago
(27-Apr-2025)
12/18 (66.67%)
$57.66 (29.98%)
526
Buy
$240
$47.55 (24.71%)
$210
4 months 14 days ago
(04-Mar-2025)
7/8 (87.5%)
$28.46 (13.45%)
474
Hold
$223
$30.55 (15.87%)
$191
4 months 15 days ago
(03-Mar-2025)
3/4 (75%)
$15.71 (7.58%)
443
Which stock is Jason Gerberry is most bullish on?
Which stock is Jason Gerberry is most reserved on?
What Year was the first public recommendation made by Jason Gerberry?